OraSure Technologies Reports 38% Revenue Decline and $68.7 Million Net Loss for Fiscal Year 2025

OraSure Technologies, Inc. reported a significant decline in its financial performance for the fiscal year ended December 31, 2025, with consolidated net revenues decreasing by 38% to $115.0 million, down from $185.8 million in 2024. The company recorded a net loss of $68.7 million, or $0.94 per share, compared to a loss of $19.5 million, or $0.26 per share, in the previous year. This downturn was primarily attributed to reduced sales in its diagnostics segment, particularly in HIV products, which were impacted by decreased funding and changing customer ordering patterns, especially in international markets. The company also experienced a 99% drop in revenues from its COVID-19 diagnostics, reflecting a significant reduction in demand as the pandemic's urgency waned.

In terms of operational changes, OraSure made strategic moves including the acquisition of BioMedomics, Inc. in November 2025, which added the SickleSCAN® test for sickle cell disease to its portfolio. This acquisition is expected to enhance the company's diagnostic offerings, particularly in markets outside the U.S. Additionally, the company has been focusing on its sample management solutions, although revenues from this segment also fell by 25% to $38.4 million, largely due to a major customer's bankruptcy.

The company’s workforce remained stable, with 500 full-time employees as of December 31, 2025, a slight decrease from 501 in the previous year. However, the company has faced challenges in maintaining sales levels, particularly in international markets, where revenues accounted for 32% of total sales in 2025, up from 11% in 2023. This growth in international sales is attributed to the expansion of its product offerings and strategic partnerships, although the company acknowledges the risks associated with geopolitical and economic conditions that could impact future sales.

Looking ahead, OraSure's management expressed cautious optimism about future growth, emphasizing the importance of regulatory approvals for new products, including a rapid molecular self-test for Chlamydia trachomatis and Neisseria gonorrhoeae, which is currently under FDA review. The company is also focused on improving its operational efficiencies and expanding its market presence, particularly in the diagnostics and sample management sectors. However, the ongoing volatility in the healthcare market, coupled with the need for continued investment in research and development, presents challenges that could affect the company's ability to achieve its financial and strategic objectives in the near term.